Vast’s ALX1 antibacterial inhalation solution gets QIDP designation

Vast Therapeutics announced that its ALX1 inhalation solution for the treatment of lung infections has received Qualified Infectious Disease Product designation from the FDA. The company describes ALX1 as a nitric oxide pro-drug, and the formulation is delivered via a PARI e-Flow nebulizer.

Earlier this year, Vast announced that it had received a grant worth almost $2 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) for development of ALX1 for the treatment of Pseudomonas aeruginosa infections in bronchiectasis patients.

Vast CEO Nathan Stasko commented, “This designation recognizes ALX1 as a significant innovation for treating bronchiectasis patients who suffer from chronic Pseudomonas infections. The takeaway is that the FDA and Vast are working together to speed access to this transformative medicine for all bronchiectasis patients, regardless of where they come from, genetic mutation or otherwise.”

Read the Vast Therapeutics press release